Elagolix in endometriosis

Effective treatment options for pain management in women with endometriosis are currently limited. Following promising phase II data, results from two phase III trials now show that elagolix — an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that suppresses oestrogen production — reduces pain symptoms in women with endometriosis-related pain. Investigators performed two similar randomized phase III trials, Elaris Endometriosis I (EM-I) and EM-II, to evaluate the efficacy and safety of 6 months of treatment with low-dose (150 mg; once daily) and high-dose (200 mg; twice daily) elagolix, compared with placebo, in women with moderate or severe endometriosis-associated pain. The two primary efficacy end points were the proportion of women who had a clinical response with respect to dysmenorrhoea and non-menstrual pelvic pain at 3 months, which were each measured as a reduction in pain scores and a decreased or stable use of rescue analgesic agents. This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 € / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access 176,64 € per year only 14,72 € per issue Buy this article - Purchase on SpringerLink - Instant access to the full article PDF. 39,95 € Prices may be subject to local taxes which are calculated during checkout References Taylor, H. S. et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1700089 (2017) Rights and permissions About this article Cite this article Bradley, C. Elagolix in endometriosis. Nat Rev Endocrinol 13, 439 (2017). https://doi.org/10.1038/nrendo.2017.74 Published: Issue date: DOI: https://doi.org/10.1038/nrendo.2017.74